TKNO vs TMO
TKNO: Teknova provides custom, high-quality, and scalable reagents essential for the discovery and commercialization of next-generation therapies, vaccines, and diagnostics. TMO: The world leader in serving science, providing a comprehensive suite of analytical instruments, laboratory supplies, and biopharma services to accelerate life sciences research and patient health outcomes.
Side-by-side fundamentals
| Metric | TKNO | TMO | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $5.85 | $694.02 | |
| Market cap | $314M | $256.6B | |
| P/E as of 2026-10-21 | n/a | 37.35 | |
| PEG as of 2026-10-21, 3-year EPS CAGR to FY2025 | n/a | 179.97 | |
| Net margin FY2025, SEC XBRL | -42.6% | +15.0% | TMO higher |
| Gross margin FY2025, SEC XBRL | +33.2% | n/a | |
| Operating margin FY2025, SEC XBRL | -41.9% | +17.4% | TMO higher |
| ROE FY2025, SEC XBRL | -25.1% | +12.6% | TMO higher |
| ROA FY2025, SEC XBRL | -16.7% | +6.1% | TMO higher |
| Debt / equity | 0.21 | 0.87 | TKNO lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +7.3% | +3.9% | TKNO higher |
| Revenue CAGR (3y) SEC XBRL | -0.7% | -0.3% | TMO higher |
| Dividend yield as of 2026-09-02 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | TMO higher |
| Beta as of 2026-09-02 | 1.77 | 0.77 | |
| 1-year return as of 2026-10-21 close | +4.1% | +24.4% | TMO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.